Cyto Wave Technologies Shares DTC Eligible

Spread the Word
Listed Under

* Cancer
* Cancer Detection

* Biotech
* Medical

* San Francisco - California - US

SAN FRANCISCO - June 15, 2014 - PRLog -- SAN FRANCISCO, CA, June 16, 2014 – Cyto Wave Technologies Inc.  (the "Company") today announced that its common shares have been accepted by the Depository Trust & Clearing Corporation (DTCC) for electronic clearing of its stock.

Brokers can now clear shares of CWAV stock electronically through DTCC. CWAV stock can now be purchased through any broker, including Scottrade and TD Ameritrade and others who had previously opted not to manually clear non-DTCC stocks.

About Cyto Wave Technologies, Inc.

The Company is developing its highly sensitive iV3 device for in vivo, real-time, non-invasive detection of metastatic CTCs (circulating tumor cells) in the bloodstream of cancer patients.  iV3 can also potentially destroy CTCs directly and is based on a proprietary photoacoustic laser technology. Additional information about the Company may be found on its website,

Safe Harbor Statement

This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the Company’s business strategy and prospects, financial performance and ability to execute its business plan; the ability of the Company to successfully develop its iV3 device; the ability of the Company to sufficiently fund the development of its iV3 device; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.


Investor Relations
Email:*** Email Verified
Tags:Cancer, Cancer Detection
Industry:Biotech, Medical
Location:San Francisco - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jun 16, 2014

Like PRLog?
Click to Share